Bluebird Bio and Gritstone Oncology signs a Research Collaboration
Shots:
- Bluebird and Gritstone collaborated to research- develop and commercialize products to treat multiple cancer using cell therapies. Gritstone will provide 10 tumor-specific targets and T-cell receptors (TCRs) in certain cases
- Bluebird bio will take care of development- manufacturing and commercial activities. Gritstone will utilize its technology platform to enable patient selection for clinical studies
- Gritstone to receive $20M upfront and additional $10M Series C equity investment from Bluebird. Gritstone is also eligible for development- regulatory and commercial milestones payments on any therapies- and royalties on certain approved therapies
/ | Ref: Bluebirdbio | Image: Business Wire
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com